MITRA Stock Overview
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Mithra Pharmaceuticals SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.22 |
| 52 Week High | €3.87 |
| 52 Week Low | €0.20 |
| Beta | 0.45 |
| 1 Month Change | -7.71% |
| 3 Month Change | -80.15% |
| 1 Year Change | -92.47% |
| 3 Year Change | -99.12% |
| 5 Year Change | -99.14% |
| Change since IPO | -98.15% |
Recent News & Updates
Recent updates
Not Many Are Piling Into Mithra Pharmaceuticals SA (EBR:MITRA) Stock Yet As It Plummets 26%
Apr 06
Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive
Feb 07Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts
Nov 09These Analysts Just Made A Huge Downgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) EPS Forecasts
Oct 05Take Care Before Diving Into The Deep End On Mithra Pharmaceuticals SA (EBR:MITRA)
May 23Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts
Aug 11Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%
Mar 13Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt
Dec 22Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 24Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt
Jun 07When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?
May 10Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?
Mar 18We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings
Feb 16Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long
Jan 21
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 29Shareholder Returns
| MITRA | BE Pharmaceuticals | BE Market | |
|---|---|---|---|
| 7D | -3.7% | -1.3% | -0.06% |
| 1Y | -92.5% | 3.4% | -5.0% |
Return vs Industry: MITRA underperformed the Belgian Pharmaceuticals industry which returned 3.4% over the past year.
Return vs Market: MITRA underperformed the Belgian Market which returned -5% over the past year.
Price Volatility
| MITRA volatility | |
|---|---|
| MITRA Average Weekly Movement | 18.2% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in BE Market | 7.7% |
| 10% least volatile stocks in BE Market | 2.5% |
Stable Share Price: MITRA's share price has been volatile over the past 3 months.
Volatility Over Time: MITRA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 270 | Christophe Marechal | www.mithra.com |
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications.
Mithra Pharmaceuticals SA Fundamentals Summary
| MITRA fundamental statistics | |
|---|---|
| Market cap | €15.31m |
| Earnings (TTM) | -€173.50m |
| Revenue (TTM) | €40.16m |
0.4x
P/S Ratio-0.1x
P/E RatioIs MITRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MITRA income statement (TTM) | |
|---|---|
| Revenue | €40.16m |
| Cost of Revenue | €21.95m |
| Gross Profit | €18.21m |
| Other Expenses | €191.71m |
| Earnings | -€173.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -2.51 |
| Gross Margin | 45.34% |
| Net Profit Margin | -432.08% |
| Debt/Equity Ratio | -258.9% |
How did MITRA perform over the long term?
See historical performance and comparison